ArticleFrontiers in neurology2025
Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma.
Yuchen Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it